{"id":94180,"date":"2026-05-28T16:31:33","date_gmt":"2026-05-28T16:31:33","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/94180\/"},"modified":"2026-05-28T16:31:33","modified_gmt":"2026-05-28T16:31:33","slug":"novo-nordisk-navigates-a-market-split-european-reimbursement-gains-offset-by-generic-erosion-in-eme","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/94180\/","title":{"rendered":"Novo Nordisk Navigates a Market Split: European Reimbursement Gains Offset by Generic Erosion in Eme"},"content":{"rendered":"

France to reimburse Wegovy from June, unlocking 1M patients, but generic Ozempic in Brazil, India, Canada erodes pricing power. Novo stock up 12% from March low, still down 36% YoY.<\/p>\n

Novo Nordisk finds itself pulled in opposing directions as 2026 progresses. On one side, France is poised to become the first European Union member to reimburse Wegovy from mid-June, unlocking an estimated one million patients. On the other, generic versions of Ozempic are chipping away at its pricing power in Brazil, India and Canada, forcing the Danish drugmaker to lean more heavily on its buyback programme and earnings resilience.<\/p>\n

France\u2019s reimbursement framework targets severely obese adults \u2014 those with a body mass index of 40 or above, or 35 with relevant comorbidities. The standard coverage rate stands at 65 percent, though most eligible patients are expected to qualify for full coverage due to underlying conditions. The programme will cost the French health system roughly 100 million euros annually and also includes Eli Lilly\u2019s Mounjaro in its initial rollout. Until now, patients paid around 300 euros a month out of pocket. The decision marks a structural shift for the European GLP?1 market and could trigger similar moves across the bloc.<\/p>\n

India offers a contrasting story of access and erosion. While the CDSCO recently approved Wegovy for adolescents aged 12 and over weighing more than 60 kilograms \u2014 a demographic advantage over Lilly\u2019s Mounjaro, which lacks that label \u2014 the country has already seen generic semaglutide hit pharmacy shelves since March. That forced price cuts in one of the fastest?growing diabetes markets. Brazil followed on May 26, approving the first generic version of Ozempic and adding another chink in Novo\u2019s global exclusivity armour.<\/p>\n

Should investors sell immediately? Or is it worth buying Novo Nordisk?<\/a><\/p>\n

The pricing pressure extends into developed markets as well. In Canada, GLP?1 drugs are already being discounted by 40 to 65 percent, with patents lapsed and competitors moving in. In the United States, CVS Health\u2019s Caremark will restore Lilly\u2019s Zepbound to its formulary from October 2026 and add the oral pill Foundayo in June, placing Novo\u2019s Wegovy and Lilly\u2019s products on equal footing for some 25 to 30 million covered lives. Meanwhile, the Trump administration\u2019s \u201cTrumpRx.gov\u201d initiative is pushing a most?favoured?nation pricing model squarely at Ozempic.<\/p>\n

The stock has felt the crosscurrents. Trading at \u20ac39.53, Novo Nordisk has recovered roughly 12 percent over the past month and sits well above its 50?day moving average, having bottomed at \u20ac30.48 in March. Yet the shares remain some 36 percent below their level a year ago, and the year?to?date decline stands at nearly 12 percent. Deutsche Bank reiterated its Hold rating with a price target of 290 Danish kroner, pointing to mounting pricing headwinds in international markets. Among analysts, six rate the stock a Buy while two recommend selling.<\/p>\n

Novo\u2019s response has been twofold. It announced a share buyback programme of up to 15 billion Danish kroner and posted first?quarter earnings that beat expectations, with earnings per share of $1.043. The message to investors is clear: the cash?flow engine still runs strongly, even if margin pressures are beginning to show.<\/p>\n

Ultimately, Novo Nordisk is juggling a widening gap between demand expansion and price compression. Reimbursement breakthroughs like France\u2019s open new revenue pools, but the relentless advance of generics in emerging markets and formulary changes in the US are steadily narrowing the moat around its blockbuster GLP?1 franchise. How effectively the company can offset that erosion will define its trajectory through the rest of 2026 and beyond.<\/p>\n

Ad<\/p>\n

Novo Nordisk Stock: New Analysis – 28 May<\/p>\n

Fresh Novo Nordisk information released. What’s the impact for investors? Our latest independent report examines recent figures and market trends.<\/p>\n

Read our updated Novo Nordisk analysis…<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"France to reimburse Wegovy from June, unlocking 1M patients, but generic Ozempic in Brazil, India, Canada erodes pricing…\n","protected":false},"author":2,"featured_media":94181,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[72,12332,12074,4135,26151,5691,3845,272,48643,13800,44768],"class_list":["post-94180","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-european","tag-gains","tag-generic","tag-market","tag-navigates","tag-nordisk","tag-novo","tag-novo-nordisk","tag-offset","tag-reimbursement","tag-split"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116653161842216742","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/94180","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=94180"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/94180\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/94181"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=94180"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=94180"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=94180"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}